Parkinson’s disease (PD) is typically diagnosed based on clinical exam, but there are tests that are available to help in diagnosis. The most commonly known is a Dopamine Transporter Scan (DaTscan) which is an imaging test in which a radioactive tracer, Ioflupane (123I) — which is also called DaTscan — is injected into the blood, where […]

How Adaptive DBS Aims to Offer More Personalized and Effective Therapy When the Food and Drug Administration (FDA) approved deep brain stimulation (DBS) for Parkinson’s disease (PD) in 2002, it revolutionized the PD treatment landscape. DBS has since become a very effective therapy for certain patients whose symptoms are no longer adequately controlled by medication […]

How Nanocarriers Overcome a Major Hurdle in Parkinson’s Treatment Delivering medications to the brain is one of the most significant challenges in modern medicine. The brain is protected by an incredibly selective shield known as the blood-brain barrier (BBB), a defense mechanism that keeps out toxins and harmful agents but also prevents many therapeutic drugs […]

What is neuromodulation and how can it be used to treat Parkinson’s disease? Medication remains the primary method of treating Parkinson’s disease (PD). However, neuromodulation, or therapies that involve the manipulation of brain circuitry, can also be very effective in controlling PD symptoms in particular clinical situations. Two current neuromodulatory techniques for PD are deep […]

Promising New Treatments for Parkinson’s: What’s in the Clinical Trial Pipeline? There remains an urgent unmet need for Parkinson’s disease (PD) treatments that slow or halt the underlying neurodegenerative process that leads to disease progression. Much research is focused on this, with clinical trials underway. It is also critical that medications continue to be developed […]